Evidence map›Paper›PMID 29667116›Full record

ArticleAnnals of surgical oncology2018

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.

Willemieke S Tummers, Sarah E Miller, Nutte T Teraphongphom, Adam Gomez, Idan Steinberg, David M Huland, Steve Hong, Sri-Rajasekhar Kothapalli, Alifia Hasan, Robert Ertsey and 8 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02736578 (Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging), which is not on this map. Cited by 103 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02736578 phase2terminatednot on this map

Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging

TypeinterventionalSponsorEben RosenthalRan2016 to 2017Enrolled8ConditionsPancreatic AdenocarcinomaArmsCetuximab-IRDye800, Cetuximab
3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 3 countries.

Willemieke S TummersDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA.
Sarah E MillerDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Nutte T TeraphongphomDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Adam GomezDepartment of Pathology, Stanford University, Stanford, CA, USA.
Idan SteinbergDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA.
David M HulandDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA.
Steve HongDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Sri-Rajasekhar KothapalliDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA.
Alifia HasanDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Robert ErtseyDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
Bert A BonsingDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Alexander L VahrmeijerDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Rutger-Jan SwijnenburgDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Teri A LongacreDepartment of Pathology, Stanford University, Stanford, CA, USA.
George A FisherDepartment of Medical Oncology, Stanford University, Stanford, CA, USA.
Sanjiv S GambhirDepartments of Radiology, Bioengineering, and Materials Science & Engineering, Molecular Imaging Program at Stanford; Canary Center at Stanford for Early Cancer Detection, Stanford University, Stanford, CA, USA.
George A PoultsidesDepartment of Surgery, Stanford University, Stanford, CA, USA.
Eben L RosenthalDepartment of Otolaryngology, Stanford University, Stanford, CA, USA. elr@stanford.edu.
Stanford University · USLeiden University Medical Center · NL

Funding

Stanford Molecular Imaging Scholars (SMIS) ProgramT32CA118681 · NCI · STANFORD UNIVERSITY · PI CRAIG S LEVIN · 2016 to 2026
$4.3M
Prototype optical device for image guided surgery with panitumumab-IRDye800R01CA190306 · NCI · STANFORD UNIVERSITY · PI ROSENTHAL, EBEN L. · 2015 to 2019
$2.6M
TRANSRECTAL ULTRASOUND AND PHOTOACOUSTIC IMAGING OF PROSTATE AND MOLECULAR IMAGINK99EB017729 · NIBIB · STANFORD UNIVERSITY · PI KOTHAPALLI, SRI RAJASEKHAR · 2014 to 2015
$183k
NCI NIH HHS R01 CA190306NCI NIH HHS T32 CA118681NIBIB NIH HHS K99 EB017729NIH Clinical Center T32 CA118681
6 · The paper itself

Abstract

backgroundOperative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor.

methodsA dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo.

resultsSeven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue.

conclusionsThe safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated.

Indexed as

Intraoperative CareAntineoplastic Agents, ImmunologicalCarcinoma, Pancreatic DuctalCetuximabCohort StudiesFluorescent DyesFollow-Up StudiesHumansMolecular ImagingMultimodal ImagingPancreatic NeoplasmsPrognosisSpectroscopy, Near-InfraredAntineoplastic Agents, ImmunologicalCetuximabFluorescent Dyes

Identifiers

PMID29667116
PMCPMC5977989
OpenAlexW2802371551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.